lifestyle.celebhomes.net
Home
Sample Page
Author:
Nxera Pharma
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
May 8, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
May 1, 2026
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
April 20, 2026
Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award
April 15, 2026
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
April 14, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
April 12, 2026
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
April 8, 2026
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
March 31, 2026
Nxera Pharma Webinar Presentation for FY2025 Financial Results
January 26, 2026
Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders
January 20, 2026
1
2
Next Page
→